Citation Information :
Bhattacharjee B, Bera RN, Bhatnagar A, Nagarajan N. Effect of Selective Serotonin Reuptake Inhibitors on Dental Implant Survival Rate in Patients with Neurological Disorders: A Systematic Review and Meta-analysis. Int J Prosthodont Restor Dent 2020; 10 (4):163-169.
Aim and objective: The aim and objective of the review was to evaluate how implant survival rate changes with the intake of selective serotonin reuptake inhibitors (SSRIs) in patients with neurological disorders.
Materials and methods: A systematic literature search was done in an electronic database (PubMed). In addition to this manual search of the references and gray literature was also done. Case reports, animal studies, literature reviews, and articles in non-English languages were not included. The Newcastle–Ottawa Scale was followed to assess the quality of the included studies. The meta-analysis was performed using statistical software Review Manager 5.03 and the outcome mean was measured by bivariate differential mean statistic with an intergroup estimate with a 95% confidence interval.
Results: A total of 344 articles were found in the PubMed database (n = 344) during the literature search. Five studies were included in the qualitative and quantitative analysis after removing duplicates and screening of titles and abstracts. Two studies were excluded by using eligibility criteria for the review. A total of 988 implants survived in the test group and 4,585 implants survived in the control group among all the studies (odds ratio: 0.41, 95% CI: 0.30–0.55). p < 0.00001 value from the analysis indicated a significant implant success rate in patients who were not taking any SSRI group of medications.
Conclusion: After evaluating the data from included studies, it can be concluded that patients taking the SSRI group of drugs for any neurological disorders had a higher chance of implant failures compared to the control group of patients.
Alvarenga MOP, Ferreira RDO, Magno MB, et al. Masticatory dysfunction by extensive tooth loss as a risk factor for cognitive deficit: a systematic review and meta-analysis. Front Physiol 2019;10:832. DOI: 10.3389/fphys.2019.00832.
Bortoluzzi MC, Traebert J, Lasta R, et al. Tooth loss, chewing ability and quality of life. Contemp Clin Dent 2012;3(4):393–397. DOI: 10.4103/0976-237X.107424.
Guillaume B. Dental implants: a review. Morphologie 2016;100(331):189–198. DOI: 10.1016/j.morpho.2016.02.002.
Pjetursson BE, Heimisdottir K. Dental implants – are they better than natural teeth? Eur J Oral Sci 2018;126(S1):81–87. DOI: 10.1111/eos.12543.
Lyketsos CG, Lopez O, Jones B, et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment. JAMA 2002;288(12):1475–1483. DOI: 10.1001/jama.288.12.1475.
Gonza´lez-Salvador MT, Arango C, Lyketsos CG, et al. The stress and psychological morbidity of the Alzheimer patient caregiver. Int J Geriatr Psychiatry 1999;14(9):701–710. DOI: 10.1002/(SICI)1099-1166(199909)14:9<701::AID-GPS5>3.0.CO;2-#.
Logsdon RG, Teri L, McCurry SM, et al. Wandering: a significant problem among community-residing individuals with Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci 1998;53(5):294–299. DOI: 10.1093/geronb/53B.5.P294.
Lyketsos CG, Steele C, Baker L, et al. Major and minor depression in Alzheimer's disease: prevalence and impact. J Neuropsychiatry Clin Neurosci 1997;9(4):556–561. DOI: 10.1176/jnp.9.4.556.
Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005;62(10):1601–1608. DOI: 10.1001/archneur.62.10.1601.
Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol 2007;64(12):1755–1761. DOI: 10.1001/archneur.64.12.1755.
Okura T, Plassman BL, Steffens DC, et al. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the aging, demographics, and memory study. J Am Geriatr Soc 2010;58(2):330–337. DOI: 10.1111/j.1532-5415.2009.02680.x.
Akushevich I, Yashkin AP, Kravchenko J, et al., Time Trends in the Prevalence of Neurocognitive Disorders and Cognitive Impairment in the United States: The Effects of Disease Severity and Improved Ascertainment.
Badea M, Muresanu DF. Dental care for patients with neurological disorders. Roman J Neurol 2008;1:10–13.
Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 2018;455(7215):894–902. DOI: 10.1038/nature07455.
Liu B, Anderson G, Mittmann N, et al. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351(9112):1303–1307. DOI: 10.1016/S0140-6736(97)09528-7.
Guobis Z, Pacauskiene I, Astramskaite I. General diseases influence on peri-implantitis development: a systematic review. J Oral Maxillofac Res 2016;7(3):e5. DOI: 10.5037/jomr.2016.7305.
Donos N, Calciolari E. Dental implants in patients affected by systemic diseases. Br Dent J 2014;217(8):425–430. DOI: 10.1038/sj.bdj.2014.911.
Marder MZ. Medical conditions affecting the success of dental implants. Compend Contin Educ Dent 2004;25:739–742.
Ouanounou A, Hassanpour S, Glogauer M. The influence of systemic medications on osseointegration of dental implants. J Can Dent Assoc 2016;82:7.
Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments. BMC Med Res Methodol 2014;14(1):45. DOI: 10.1186/1471-2288-14-45.
Howick J, Chalmers L, Glasziou P, et al., The 2011 Oxford CEBM Levels of Evidence (Introductory Document); 2011. Available from https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence.
Packer M, Nikitin V, Coward T, et al. The potential benefits of dental implants on the oral health quality of life of people with Parkinson's disease. Gerodontology 2009;26(1):11–18. DOI: 10.1111/j.1741-2358.2008.00233.x.
Ekfeldt A, Zellmer M, Carlsson GE. Treatment with implant-supported fixed dental prostheses in patients with congenital and acquired neurologic disabilities: a prospective study. Int J Prosthodont 2013;26(6):517–524. DOI: 10.11607/ijp.3511.
Wu X, Al-Abedalla K, Rastikerdar E, et al. Selective serotonin reuptake inhibitors and the risk of osseointegrated implant failure: a cohort study. J Dent Res 2014;93(11):1054–1061. DOI: 10.1177/0022034514549378.
Chrcanovic BR, Kisch J, Albrektsson T, et al. Is the intake of selective serotonin reuptake inhibitors associated with an increased risk of dental implant failure? Int J Oral Maxillofac Surg 2017;46(6):782–788. DOI: 10.1016/j.ijom.2017.01.016.
Altay MA, Sindel A, Özalp Ö, et al. Does the intake of selective serotonin reuptake inhibitors negatively affect dental implant osseointegration? a retrospective study. J Oral Implantol 2018;44(4):260–265. DOI: 10.1563/aaid-joi-D-17-00240.
Deepa V, Mujawar K, Dhillon K, et al. Prognostic implication of selective serotonin reuptake inhibitors in osseointegration of dental implants: a 5-year retrospective study. J Contemp Dent Pract 2018;19(7):842–846. DOI: 10.5005/jp-journals-10024-2345.
Carr AB, Gonzalez RLV, Jia L, et al. Relationship between selective serotonin reuptake inhibitors and risk of dental implant failure. J Prosthodont 2019;28(3):252–257. DOI: 10.1111/jopr.13015.
Langer A. Prosthodontic failures in patients with systemic disorders. J Oral Rehabil 1979;6(1):13–19. DOI: 10.1111/j.1365-2842.1979.tb00399.x.
Heckmann SM, Heckmann SG, Weber PH. Clinical outcomes of three Parkinson's disease patients treated with mandibular implant overdentures. Clin Oral Implants Res 2000;11(6):566–571. DOI: 10.1034/j.1600-0501.2000.011006566.x.
Chu FC, Deng FL, Siu AS, et al. Implant-tissue supported, magnet retained mandibular overdenture for an edentulous patient with Parkinson's disease: a clinical report. J Prosthet Dent 2004;91(3):219–222. DOI: 10.1016/j.prosdent.2003.12.014.
Rogers JO. Implant-stabilised complete mandibular denture for a patient with cerebral palsy. Dent Update 1995;22:23–26.
Nam SS, Lee JC, Kim HJ, et al. Serotonin inhibits osteoblast differentiation and bone regeneration in rats. J Periodontol 2016;87(4):461–469. DOI: 10.1902/jop.2015.150302.
Battaglino R, Fu J, Spate U, et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004;19(9):1420–1431. DOI: 10.1359/JBMR.040606.
Kahl KG, Greggersen W, Rudolf S, et al. Bone mineral density, bone turnover, and osteoprotegerin in depressed women with and without borderline personality disorder. Psychosom Med 2006;68(5):669–674. DOI: 10.1097/01.psy.0000237858.76880.3d.
Tsapakis EM, Gamie Z, Tran GT, et al. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2012;27(3):156–169. DOI: 10.1016/j.eurpsy.2010.10.006.